What are the recommended oral acyclovir dosing regimens for adult herpes simplex infections (primary genital herpes, recurrent genital herpes, oral labial herpes) and for shingles, and how should the dose be adjusted in immunocompromised patients or those with impaired renal function?

Acyclovir Dosing for Herpes Infections

For adult herpes simplex and zoster infections, use the FDA-approved oral acyclovir regimens: 200 mg five times daily for 7-10 days for primary genital herpes, 800 mg twice daily for 5 days for recurrent genital herpes, and 800 mg five times daily for 7-10 days for shingles, with dose adjustments required for renal impairment. 1

Primary Genital Herpes (First Episode)

• Standard regimen: Acyclovir 200 mg orally 5 times daily for 7-10 days or until clinical resolution 2
• For herpes proctitis specifically: 400 mg orally 5 times daily for 10 days 2
• Treatment should be initiated as early as possible after symptom onset 1
• Higher doses (400 mg five times daily) have been studied for first-episode oral infections and proctitis, though it remains unclear if these mucosal infections require higher dosing than standard genital herpes 3
• Research comparing 4 g daily versus 1 g daily found no additional clinical benefit from higher doses, though gastrointestinal adverse effects increased to 8% with higher dosing 4

Recurrent Genital Herpes

Three equivalent episodic treatment options: 2

• Acyclovir 200 mg orally 5 times daily for 5 days
• Acyclovir 400 mg orally 3 times daily for 5 days
• Acyclovir 800 mg orally twice daily for 5 days (most convenient dosing)

Key timing consideration: Treatment must be initiated at the earliest sign of prodrome or within 2 days of lesion onset for benefit 2. Most immunocompetent patients with recurrent disease do not benefit from acyclovir if treatment is delayed 2. The 800 mg twice-daily regimen may be particularly effective for treating vesicles already present in male patients 5.

Suppressive Therapy for Frequent Recurrences

For patients with ≥6 recurrences per year: 2

• Primary regimen: Acyclovir 400 mg orally twice daily
• Alternative: Acyclovir 200 mg orally 3-5 times daily (titrate to lowest effective dose)
• Reduces recurrence frequency by at least 75% 2
• Safety documented for up to 5-6 years of continuous use 2, 3
• Reassess after 1 year to determine if continued suppression is needed, as recurrence frequency naturally decreases over time in many patients 2, 3
• Does not eliminate asymptomatic viral shedding or transmission risk 2

Oral Labial Herpes (Cold Sores)

• Suppressive therapy: Acyclovir 400 mg orally twice daily for patients with frequently recurrent disease (≥6 episodes/year) 6
• This regimen resulted in 53% reduction in clinical recurrences and 71% reduction in culture-positive recurrences compared to placebo 6
• Short-course high-dose regimens (valacyclovir, famciclovir) are FDA-approved for episodic treatment, though specific acyclovir episodic dosing for herpes labialis is less well-established 7

Herpes Zoster (Shingles)

Standard regimen: Acyclovir 800 mg orally every 4 hours (5 times daily) for 7-10 days 1, 8

• Must be initiated within 72 hours of rash onset for optimal benefit 1
• The 800 mg five-times-daily dose is superior to 400 mg five-times-daily, significantly reducing viral shedding, accelerating healing, and decreasing acute pain severity 8
• Also reduces post-herpetic neuralgia, with most significant benefit in the first 3 months post-infection 8
• Oral acyclovir provides particular benefit in patients over 50 years of age and those with rash outside the trunk distribution 9

Severe Disease Requiring Hospitalization

For disseminated infection, encephalitis, pneumonitis, hepatitis, or CNS complications: 2, 3

• Acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution
• IV therapy is mandatory for severe disease in both immunocompetent and immunocompromised patients 2

Immunocompromised Patients

• Require more aggressive therapy with higher doses and longer duration 2
• Suggested regimen: Acyclovir 400 mg orally 3-5 times daily (similar to dosing for other immunocompromised conditions) 3
• May have prolonged episodes with extensive disease 2
• HIV-infected patients should be monitored closely, as healing may be slower and treatment failures occur 3
• Critical warning: Valacyclovir doses of 8 g/day have been associated with hemolytic uremic syndrome/thrombotic thrombocytopenic purpura in immunocompromised patients; standard genital herpes doses remain safe 3
• Acyclovir-resistant strains may emerge, requiring alternative antiviral agents 2

Renal Dose Adjustments

Mandatory dose modifications based on creatinine clearance: 1

For 200 mg every 4 hours (5x daily):

• CrCl >10: No adjustment (200 mg every 4 hours)
• CrCl 0-10: 200 mg every 12 hours

For 400 mg every 12 hours:

• CrCl >10: No adjustment (400 mg every 12 hours)
• CrCl 0-10: 200 mg every 12 hours

For 800 mg every 4 hours (5x daily):

• CrCl >25: No adjustment (800 mg every 4 hours)
• CrCl 10-25: 800 mg every 8 hours
• CrCl 0-10: 800 mg every 12 hours

Hemodialysis patients:

• Plasma half-life during dialysis is ~5 hours with 60% decrease in concentrations after 6-hour dialysis 1
• Administer supplemental dose after each dialysis session 1

Peritoneal dialysis:

• No supplemental dosing needed after interval adjustment 1

Critical Safety Considerations

• Maintain adequate hydration to prevent renal dysfunction, especially important when using potentially nephrotoxic agents concurrently 1
• Caution with concomitant nephrotoxic drugs due to increased risk of renal dysfunction and reversible CNS symptoms 1
• Acyclovir is generally well-tolerated with minimal adverse events in immunocompetent patients 7, 10
• Neither eradicates latent virus nor prevents future recurrences after discontinuation 2

Patient Counseling Essentials

• Acyclovir is not a cure for herpes infections 1
• Does not prevent transmission to sexual partners; abstain from sexual activity when lesions present 2
• Transmission can occur during asymptomatic periods through viral shedding 2
• Condom use should be encouraged during all sexual exposures 2
• Women of childbearing age must inform obstetric providers about genital herpes due to neonatal infection risk 2
• For recurrent episodes, initiate therapy at first sign of prodrome for maximum benefit 2, 1